Source and scope
This summary is bounded to the recommendations, population and decisions covered by Canadian Guideline for Opioids for Chronic Non-Cancer Pain. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Canadian opioid guideline
Source-attributed clinical priorities
- Use a biopsychosocial assessment that identifies pain mechanism, function, sleep, mood, substance use and patient priorities.
- Emphasize active self-management and non-opioid strategies, with measurable functional goals for any treatment trial.
- If opioids are considered, apply the Canadian guideline’s risk assessment, dose caution, monitoring and tapering principles.
- Separate pain intensity from pain-related disability and agree on a small number of functional outcomes.
sources for this section:Canadian opioid guideline
Practical assessment and management workflow
1
Clarify pain onset, distribution, mechanism, previous investigations and treatments, sleep, mood and occupational context.
2
Examine for neurologic deficit, inflammation, fracture, infection or malignancy before assigning chronic primary pain.
3
Build a paced activity, rehabilitation and psychological plan and use medication only for a defined therapeutic trial.
4
Review function, adverse effects and goal attainment and taper ineffective medicine collaboratively.
sources for this section:Canadian opioid guideline
Safety, red flags and urgent escalation
- New major neurologic deficit, spinal emergency features, systemic illness or rapidly escalating pain requires reassessment.
- Assess opioid overdose, sleep apnea, sedative co-use and substance-use risk and offer naloxone where indicated.
- Do not force a rapid opioid taper in a stable patient; unsafe use requires an individualized, supported plan.
sources for this section:Canadian opioid guideline
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Canadian opioid guideline
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Canadian opioid guideline
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- National Pain Centre, McMaster UniversityCanadian Guideline for Opioids for Chronic Non-Cancer Painaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.